Biofrontera (BFRI) investor relations material

Key presentations and company updates

• Biofrontera highlighted strong revenue growth, with 2024 revenues at $37.3 million and significant improvement in gross margins following the acquisition of Ameluz's U.S. rights and manufacturing responsibilities.

• Ameluz, Biofrontera's photodynamic therapy drug, is expanding indications beyond actinic keratosis, with new FDA submissions for basal cell carcinoma and ongoing trials for acne and body-wide use.

• LSL Pharma Group reported rapid expansion, targeting over CAD 65 million in 2026 revenue, driven by three segments: contract manufacturing, eye care, and a newly acquired OTC private label business.

• LSL's eye care division is set for major growth, with new in-licensed eye drops and increased manufacturing capacity, aiming for 50% of company revenue and 70% of EBITDA in coming years.

• Both companies emphasized ongoing M&A activity, integration of recent acquisitions, and a focus on quality and sustainable growth.

Strategic initiatives and growth drivers

• Biofrontera expects continued double-digit revenue growth, supported by new product indications, expanded reimbursement, and a refined commercial strategy.

• LSL Pharma is leveraging synergies from recent acquisitions, expanding its product portfolio, and increasing manufacturing capacity to drive organic and inorganic growth.

• LSL's recent acquisition of Juno OTC is expected to add CAD 20-25 million in annual revenue and enhance distribution for ophthalmic products across Canada.

• Both companies are investing in R&D and licensing to broaden their product offerings and enter new markets, including the U.S. for LSL's ophthalmic products.

• Financial discipline and balance sheet strength are priorities, with break-even targeted for Biofrontera in 2026 and LSL aiming for $100 million in revenue within two years.

Analyst and management perspectives

• Analyst sessions provided insights into sector trends, reimbursement dynamics, and the importance of field therapy in dermatology.

• Management from both companies stressed the importance of quality, customer retention, and operational efficiency as key competitive advantages.

• Integration of recent acquisitions and scaling up manufacturing are seen as both challenges and opportunities for 2026.

• Both companies are positioning themselves for leadership in their respective niches through innovation, market expansion, and strategic partnerships.

• Investor engagement and transparency were highlighted, with open invitations for follow-up meetings and Q&A.